Key result
NOACs were superior to warfarin for the prevention of the composite of stroke and systemic embolism in patients with atrial fibrillation (OR 0.85; 95% CI 0.75 to 0.98).
Why the study?
Do NOACs reduce the composite of stroke or systemic embolic events compared to warfarin in patients with atrial fibrillation?
Systematic Review (n=77,011)
Do NOACs reduce the composite of stroke or systemic embolic events compared to warfarin in patients with atrial fibrillation?
Odds Ratio: 0.85 (95% CI 0.75–0.98)
NOACs are superior to warfarin for preventing stroke and systemic embolism in AF patients, with significantly lower intracranial hemorrhage and mortality, though switching from NOACs to warfarin poses a high risk of adverse events.
No takes yet. Share an insight, caveat, or question.
NOACs warrant first-line preference over warfarin in AF; confirms superiority for stroke prevention across trials.
Hicks et al. (2016) conducted a systematic review in Atrial fibrillation (n=77,011). Novel oral anticoagulants (NOACs) vs. Warfarin was evaluated on Composite of stroke or systemic embolic events (OR 0.85, 95% CI 0.75 to 0.98). NOACs were superior to warfarin for the prevention of the composite of stroke and systemic embolism in patients with atrial fibrillation (OR 0.85; 95% CI 0.75 to 0.98).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: